*ST大药
(603963)
| 流通市值：2.59亿 | | | 总市值：2.59亿 |
| 流通股本：2.20亿 | | | 总股本：2.20亿 |
| 报告期 | 2025-12-31 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 99,205,241.74 | 53,112,353.93 | 67,764,057.45 | 47,647,377.83 |
| 营业收入 | 99,205,241.74 | 53,112,353.93 | 67,764,057.45 | 47,647,377.83 |
| 二、营业总成本 | 121,753,527.45 | 65,657,917.07 | 98,026,449.2 | 68,668,071.49 |
| 营业成本 | 90,073,022.79 | 49,618,321.13 | 64,297,633.38 | 43,958,168.16 |
| 税金及附加 | 3,044,348.34 | 1,533,697.83 | 2,802,226.59 | 2,125,525.55 |
| 销售费用 | 12,939,217.75 | 6,140,049.52 | 13,386,355.11 | 9,698,595.06 |
| 管理费用 | 15,298,453.34 | 8,130,609.84 | 15,354,707.96 | 11,379,568.45 |
| 研发费用 | 414,372.87 | 215,752.64 | 1,417,345.29 | 886,500.25 |
| 财务费用 | -15,887.64 | 19,486.11 | 768,180.87 | 619,714.02 |
| 其中:利息费用 | 91,577.41 | 91,577.41 | 942,764.69 | 738,330.98 |
| 其中:利息收入 | 119,844.79 | 79,959.86 | 186,932.45 | 128,556.73 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | 1,848,658.74 | 1,848,658.74 |
| 加:投资收益 | - | - | 336,849.73 | 336,849.73 |
| 资产处置收益 | - | - | 68,015.17 | 28,634.64 |
| 资产减值损失(新) | 2,564,548.2 | -53,226.64 | -1,259,984.68 | -163,374.53 |
| 信用减值损失(新) | -81,445 | -48,672.29 | -515,660 | -353,020.17 |
| 其他收益 | 509,907.14 | 52,126.73 | 178,638.24 | 156,209.3 |
| 四、营业利润 | -19,555,275.37 | -12,595,335.34 | -29,605,874.55 | -19,166,735.95 |
| 加:营业外收入 | 102,768.02 | 46,354.28 | 479,413.85 | 74,032.25 |
| 减:营业外支出 | 8,148.95 | 5,478.3 | 152,630.89 | 36,538.61 |
| 五、利润总额 | -19,460,656.3 | -12,554,459.36 | -29,279,091.59 | -19,129,242.31 |
| 减:所得税费用 | 10,041.77 | 29,676.62 | 4,359,455.31 | 605,829.75 |
| 六、净利润 | -19,470,698.07 | -12,584,135.98 | -33,638,546.9 | -19,735,072.06 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -19,470,698.07 | -12,584,135.98 | -33,638,546.9 | -19,735,072.06 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -19,470,698.07 | -12,584,135.98 | -33,638,546.9 | -19,735,072.06 |
| 扣除非经常损益后的净利润 | -20,075,118.44 | -12,663,988.09 | -36,397,491.74 | -22,403,638.76 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.09 | -0.06 | -0.15 | -0.09 |
| (二)稀释每股收益 | -0.09 | -0.06 | -0.15 | -0.09 |
| 九、综合收益总额 | -19,470,698.07 | -12,584,135.98 | -33,638,546.9 | -19,735,072.06 |
| 归属于母公司股东的综合收益总额 | -19,470,698.07 | -12,584,135.98 | -33,638,546.9 | -19,735,072.06 |
| 公告日期 | 2026-04-29 | 2025-08-29 | 2025-04-25 | 2024-10-31 |
| 审计意见(境内) | 标准无保留意见 | | 标准无保留意见 | |